56 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
4 Aug 22
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update
4:25pm
includes a mid-single digit royalty on net sales payable through the first half of 2024.
Research and development (R&D) expense for the three months … studies were completed in 2021, partially offset
by higher compensation expense. For the six months ended June 30, 2022 and 2021, R&D expense
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
6 Aug 20
Coherus BioSciences Reports Second Quarter 2020 Financial Results
4:07pm
in a gross profit margin of 93%.
Research and development (R&D) expense for the second quarter of 2020 was $26.2 million, as compared to $18.9 million … for the same period in 2019. R&D expense for the six months ended June 30, 2020 was $59.3 million, as compared to $37.7 million for the same period
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
8 May 23
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
4:16pm
that was damaged during processing at one of our manufacturers.
Research and development (R&D) expense for the three months ended March 31, 2023 … was $34.2 million. R&D expense for the three months ended March 31, 2022 was $82.9 million, which included a $35 million option exercise fee paid to Junshi
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
9 May 24
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
4:17pm
by higher royalty costs and an increase in product costs from the mix of products sold and the launch of new products.
Research and development (R&D) expense … $175.0 million of the total $250.0 in principal on Coherus’ 2027 Term Loans in April 2024.
2024 R&D and SG&A Expense Guidance
Coherus projects
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
5 May 22
Coherus BioSciences Reports First Quarter 2022 Results
12:00am
–
– Toripalimab BLA resubmission expected by mid-summer –
– UDENYCA® delivers 1st quarter 2022 net sales of $60.1 million –
– 2022 R&D and SG&A expense guidance … 2022 R&D and SG&A expenses. See “2022 R&D and SG&A Expense Guidance” section below.
“As we prepare for as many as four new product launches in 2022
8-K
EX-99.1
u1xf9cy8f8ay rq1
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
8-K
EX-99.1
0gauwga
8 Aug 18
Coherus BioSciences Reports Corporate Highlights and Second Quarter 2018 Financial Results
4:10pm
8-K
EX-99.1
zfd874eel7
6 Nov 23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
4:31pm
8-K
EX-99.1
acn3d
5 Aug 21
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
4:06pm
8-K
EX-99.1
mp1uqk9
23 Mar 15
Coherus BioSciences Reports Fourth Quarter and Year End 2014
12:00am
8-K
EX-99.1
30qmr
8 Nov 21
Coherus BioSciences Reports Third Quarter 2021 Results
4:06pm
8-K
EX-99.1
71emwqsz7zuedpj
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
8-K
EX-99.1
6br40m
5 Nov 20
Coherus BioSciences Reports Third Quarter 2020 Financial Results
4:07pm
8-K
EX-99.1
l65g9sdnipyf
24 Feb 21
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
4:05pm
8-K
EX-99.1
x7okfte2
7 May 20
Coherus BioSciences Reports First Quarter 2020 Financial Results
4:02pm
8-K
EX-99.1
tc5167vq cv
8 Nov 22
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
4:01pm
8-K
EX-99.1
20r5ur4
15 Dec 14
Coherus BioSciences Reports Third Quarter 2014 Financial and Operating Results
12:00am
8-K
EX-99.1
72zm7n3rcnzl
6 May 21
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
4:24pm
8-K
EX-99.1
1ht51h
8 Nov 18
Coherus BioSciences Reports Corporate Highlights and Third Quarter 2018
4:08pm
8-K
EX-99.1
gpvn3tantk 3ea
27 Feb 20
Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results
4:16pm